Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 268

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Imatinib mesylate in chordoma

Open access
Casali, Paolo G., Messina, Antonella, Stacchiotti, Silvia, Tamborini, Elena, Crippa, Flavio, Gronchi, Alessandro, Orlandi, Rosaria, Ripamonti, Carla, Spreafico, Carlo, Bertieri, Raffaello, Bertulli, Rossella, Colecchia, Maurizio, Fumagalli, Elena, Greco, Angela, Grosso, Federica, Olmi, Patrizia, Pierotti, Marco A., Pilotti, Silvana·2004·Cancer
DOI 10.1002/cncr.20618
Open this paper in CoChat — free account

Abstract

BACKGROUND: To the authors' knowledge, no effective medical therapy currently is available for advanced chordoma. Imatinib mesylate is a tyrosine kinase inhibitor targeting platelet‐derived growth factor receptor‐β (PDGFRB), BCR‐ABL, and KIT. METHODS: Six patients with advanced chordoma were treated with imatinib mesylate at a dose of 800 mg daily. In all patients, the tumor was found to be positive for PDGFRB, and in four patients PDGFRB was shown to be phosphorylated/expressed. RESULTS: After a treatment period of ≥ 1 year, overt tumor liquefaction was evident on computed tomography (CT) scan in the first patient. In previous months, a decrease in contrast enhancement on magnetic resonance imaging (MRI) and a decrease in glucose uptake on positron emission tomography (PET) were detected. Similar signs on MRI and PET were observed in subsequent patients, who had a shorter treatment period. One of these patients initially was removed from therapy and then was readmitted to therapy because of difficulties with regard to tumor response assessment; 1 month after the reinitiation of therapy, an overt decrease in tumor density was visible on CT scan in this patient. In four of five symptomatic patients, a subjective improvement was observed early in the course of treatment. The first patient died after 17 months, with a sizeable, mostly liquefied mass. Another patient died early, apparently of unrelated causes. The remaining patients were on therapy at the time of last follow‐up. CONCLUSIONS: Imatinib mesylate has been found to have antitumor activity in patients with chordoma. This activity might be mediated by inactivation of PDGFRB. Tumor response manifests through patterns that are similar to those observed in patients with gastrointestinal stromal tumors who respond to molecular‐targeted therapy, but evolves more slowly. The benefit to the patient entailed by this pattern of tumor response in chordoma needs to be elucidated, but may be limited in the presence of significant local disease. Cancer 2004. © 2004 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.20618

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 268

Metadata

Authors
Casali, P. G., Messina, A., Stacchiotti, S., Tamborini, E., Crippa, F., Gronchi, A., Orlandi, R., Ripamonti, C., Spreafico, C., Bertieri, R., Bertulli, R., Colecchia, M., Fumagalli, E., Greco, A., Grosso, F., Olmi, P., Pierotti, M. A., & Pilotti, S.
Venue
Cancer
Publisher
Wiley
Published
2004-10-18
Volume
101
Issue
9
Pages
2086-2097
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
DOI
10.1002/cncr.20618
OpenAlex
W2054238713
Cited by
268
References
13
FWCI
6.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Imatinib mesylate in chordoma. https://app.cochat.ai/papers/10.1002/cncr.20618
The paper
Casali, P. G., Messina, A., Stacchiotti, S., Tamborini, E., Crippa, F., Gronchi, A., Orlandi, R., Ripamonti, C., Spreafico, C., Bertieri, R., Bertulli, R., Colecchia, M., Fumagalli, E., Greco, A., Grosso, F., Olmi, P., Pierotti, M. A., & Pilotti, S. (2004). Imatinib mesylate in chordoma. Cancer. https://doi.org/10.1002/cncr.20618

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.